Subscribe To
89bio publishes positive results from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) in nature medicine
– Published data showed consistent and significant reductions in triglycerides, atherogenic lipoproteins and liver fat, and pegozafermin’s favorab...
June 24, 2023, 9:05 am
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with...
March 4, 2023, 6:30 pm
89bio presents new analysis of data from phase 2 entrigue trial of pegozafermin in patients with severe hypertriglyceridemia (shtg) at american college of cardiology’s annual scientific session togeth
– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with...
March 4, 2023, 6:30 pm
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio to present additional pegozafermin data in severe hypertriglyceridemia from phase 2 entrigue study at american college of cardiology's annual scientific session together with world congress of c
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
February 21, 2023, 8:00 am
89bio: nash data next year may change things for the better
ETNB stock has remained depressed for a long time. Not even solid shtg data could change that....
August 23, 2022, 4:26 am
This analyst thinks 89bio's pegozafermin data has exceeded expectations
In June, 89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertrigl...
July 11, 2022, 2:24 pm
89bio posts promising pegozafermin data for severe hypertriglyceridemia
89bio Inc (NASDAQ: ETNB) announced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia...
June 29, 2022, 6:07 am